FDA’s OPQ 2021 report focuses on pandemic responses

FDA’s OPQ 2021 report focuses on pandemic responses

Source: 
RAPS.org
snippet: 

Onsite inspections will remain the “irreplaceable standard” and are not going away anytime soon, despite the heavy reliance on remote tools to assess medicine manufacturing facilities during the coronavirus pandemic, officials from the US Food and Drug Administration noted in their 2021 report on the Office of Pharmaceutical Quality (OPQ).